Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2369616 | 0.83 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL2369612 | 0.83 | F2 (0.40) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL446590 | 0.74 | F2 (0.44) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL9965535 | 0.73 | F2 (0.50) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL14165295 | 0.73 | F2 (0.52) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL4840952 | 0.68 | CA1 (0.35) | CA1CA2 | |
| SCHEMBL6491985 | 0.65 | F2 (0.53) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL21661932 | 0.64 | F2 (0.56) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL183325 | 0.64 | F2 (1.00) | F2PRSS1PRSS2PRSS3CA1 | |
| SCHEMBL22490111 | 0.64 | F2 (0.50) | F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434753-B2 | Modified creatine compounds | GENCIA CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-20150005258-A1 | Modified Creatine Compounds | Genci Corporation (US) | 2015-01-01 | — | — | US | disclosed |
| EP-1663245-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | ASTELLAS PHARMA INC. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1994035-A1 | CEPHEM COMPOUNDS AND USE AS ANTIMICROBIAL AGENTS | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007119511-A1 | CEPHEM COMPOUNDS AND USE AS ANTIMICROBIAL AGENTS | ASTELLAS PHARMA INC. (JP) | 2007-10-25 | — | — | WO | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-7192943-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| US-20050096306-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-05 | — | — | US | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | F2 707/4885PRSS1 3381/4885PRSS2 3776/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | F2 1386/4885PRSS1 3706/4885PRSS2 3734/4885 |
| US-20050096306-A1 | Cephem compounds | CEP170, ASS1, C1S | F2 445/4885PRSS1 3616/4885PRSS2 3830/4885 |
| US-20150005258-A1 | Modified Creatine Compounds | CKMT1A; CKMT1B, SLC25A20, ARG2 | F2 2678/4885PRSS1 1719/4885PRSS2 2131/4885 |
| US-20090012054-A1 | Cephem Compounds and Use as Antimicrobial Agents | CEP170, Q6ZSR9, H1-10 | F2 1431/4885PRSS1 3312/4885PRSS2 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.